U.S. market Open. Closes in 4 hours 5 minutes

ERYP | ERYTECH Pharma S.A. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for ERYP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak.

Valuation (24%)

Company Industry
P/E Ratio (TTM) 28.04 -23.05
PEG Ratio (TTM) 0.28 15.47
P/S Ratio (TTM) N/A 49.46
P/B Ratio (TTM) N/A 18.87
P/FCF Ratio (TTM) N/A -3.27
Price to 5YR AVG Earnings Ratio -0.33 -3.55
Price to 5YR AVG FCF Ratio -0.92 -9.37

Profitability (5%)

Company Industry
ROA (TTM) N/A -5.14%
ROE (TTM) 6.80% 16.69%
Net Profit Margin (TTM) N/A -1,583.93%
ROIC 5YR AVG -379.85% 15.15%

Growth (27%)

4QTR AVG 3YR AVG 5YR AVG
EPS 71.74% -30.71% 10.13%
Revenue N/A -39.57% -23.74%
Net Income 67.62% -31.64% 6.26%
Cash Flow -12.90% -29.56% -10.88%

Health (4%)

Company Industry
Current Ratio (TTM) N/A 6.13
Quick Ratio (TTM) N/A 5.85
D/E Ratio (TTM) N/A -15.81
Interest Coverage (TTM) -2.64 -1.57
Piotroski F-Score 2 5
Altman Z-Score N/A 14.12
LTL to 5YR AVG FCF -0.20 0.17
Shares Outstanding Growth 5YR AVG 12.45% 123.44%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙